Log in  First Connection?

LungArchives

Nomogram and risk-score for predicting overall survival and risk stratification in patients with sarcomatoid non-small cell lung cancer: a multicenter study of 135 patients
Lung
 4 min.

 Published on 15/07/2025 |  Original article (Full-text)  | Tang Wenjian et al. | BMC Pulmonary Medicine 2025; 25(1): 330

Sarcomatoid non-small cell lung cancer (s-NSCLC), a rare histological variant accounting for approximately 0.4% of all pulmonary malignancies, is pathologically defined by the coexistence of epithelial and mesenchymal components [1, 2]. As a highly heterogeneous subtype, s-NSCLC is frequently diagnosed...

The impact of comorbidities on the all-cause mortality of surgically treated non-small cell lung cancer patients - visualization with the aid of a comorbidome
Lung
 6 min.

 Published on 08/07/2025 |  Original article (Full-text)  | Zimmermann Julia et al. | BMC Surgery 2025; 25(1): 285

In 2020 lung cancer was the second most common cancer and the leading cause for cancer death [1]. Surgery, if possible, is known as the first choice of treatment. Lobectomy or segmentectomy are the standard procedures for anatomical resection. They are mainly performed by video-assisted thoracoscopic...

Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus
Lung
 1 min.

 Published on 01/07/2025 |  Original article (Full-text)  | Hampig Raphael Kourie et al. | Future Oncology 2025; aop:10.1080/14796694.2025.2518911

Lung cancer is the leading cause of cancer-related death and the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. In the Middle East and North Africa (MENA) region, lung cancer ranks second in incidence and cancer mortality,...

Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
Lung
 1 min.

 Published on 24/06/2025 |  Original article (Full-text)  | Nazmul Hasan & Misako Nagasaka et al. | Expert Review of Respiratory Medicine 2025; 19(3): 223-32

The first-line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on the positive PFS and OS results from the FLAURA study. This paper reviews and...

Unraveling the role of HDAC3 as an immunotherapy prognostic biomarker and therapeutic target in advanced non-small cell lung cancer
Lung
 8 min.

 Published on 17/06/2025 |  Original article (Full-text)  | Dai Liyuan et al. | Respiratory Research 2025; 26(1): 214

According to the 2020 GLOBOCAN report, lung cancer is the second most commonly diagnosed cancer worldwide, accounting for 11.4% of new cases, and it has the highest mortality rate, responsible for 18% of cancer-related deaths [1]. Non-small cell lung cancer (NSCLC) represents approximately 85% of these...